Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ: RVMD ) with a Buy and raises the price target from $210 to $231.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $210
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ: RVMD ) with a Buy and raises the price target from $179 to $210.